ArticleDigital health
Lactate dehydrogenase-to-albumin ratio as a predictor of 28-day mortality in critically Ill patients with gastrointestinal cancers: Insights from machine learning and the Medical Information Mart for Intensive Care IV database.
Article in Digital health. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Prognostic Value of the Gustave Roussy Immune Score in Patients with Locally Advanced Gastric Cancer Receiving Neoadjuvant FLOT Chemotherapy: A Retrospective Cohort Study.Diagnostics (Basel, Switzerland) · 2026Article
- Admission Biomarkers as Predictors of Mortality in Comatose Patients in the Intensive Care Unit: A Retrospective Pilot Study.Diagnostics (Basel, Switzerland) · 2026Article
- Time-Series modeling for predicting mortality risk in intensive care unit patients with pulmonary inflammation.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To determine whether the lactate dehydrogenase-to-albumin ratio (LDAR) predicts 28-day mortality in critically ill patients with gastrointestinal (GI) malignancies and to quantify its incremental value in machine learning (ML) models. Methods: We conducted a retrospective cohort study in Medical Information Mart For Intensive Care IV (2008-2019). Adults with GI malignancies who met Sepsis-3 within 24 h of their first intensive care unit (ICU) admission were included. LDAR was computed from laboratory results obtained within 24 h. The primary outcome was 28-day all-cause mortality. Associations were estimated with multivariable logistic regression; nonlinearity was evaluated using restricted cubic splines. Multiple ML classifiers (AdaBoost, XGBoost, random forest) were trained with a 7:3 split and 5-fold cross-validation. Discrimination (area under the curve-AUC), clinical utility (decision-curve analysis), and interpretability (Shapley additive explanation-SHAP) were assessed. Prespecified subgroup analyses stratified by metastatic status and infection site were performed. Covariates included age, sex, weight, vital signs, Sequential Organ Failure Assessment, and metastatic status. Missingness was handled with multiple imputation by chained equations. Results: Among 1177 patients, 28-day mortality was 48.4%. Higher LDAR was independently associated with death; the adjusted odds ratio for Q4 vs Q1 was 5.15 (95% CI 3.52-7.61; Conclusion: LDAR is a simple, interpretable, and independently prognostic biomarker for 28-day mortality in ICU patients with GI malignancies. Incorporating LDAR into ML models improved discrimination and decision benefit over conventional severity scores, supporting LDAR-based early risk stratification. External multicenter validation and evaluation of dynamic LDAR trajectories are warranted, and transparent analytic reporting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.